These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 2868748)

  • 1. Studies with fenoldopam, a dopamine receptor DA1 agonist, in essential hypertension.
    Harvey JN; Worth DP; Brown J; Lee MR
    Br J Clin Pharmacol; 1986 Jan; 21(1):53-61. PubMed ID: 2868748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of oral fenoldopam (SKF 82526-J), a peripheral dopamine receptor agonist, on blood pressure and renal function in normal man.
    Harvey JN; Worth DP; Brown J; Lee MR
    Br J Clin Pharmacol; 1985 Jan; 19(1):21-7. PubMed ID: 2858215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemodynamic, renal, and neurohumoral effects of a selective oral DA1 receptor agonist (fenoldopam) in patients with congestive heart failure.
    Francis GS; Wilson BC; Rector TS
    Am Heart J; 1988 Aug; 116(2 Pt 1):473-9. PubMed ID: 2899970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of fenoldopam, a specific dopamine receptor agonist, on blood pressure and left ventricular function in systemic hypertension.
    Caruana MP; Heber M; Brigden G; Raftery EB
    Br J Clin Pharmacol; 1987 Dec; 24(6):721-7. PubMed ID: 2894216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular and renal profile of acute peripheral dopamine1-receptor agonism with fenoldopam.
    Glück Z; Jossen L; Weidmann P; Gnädinger MP; Peheim E
    Hypertension; 1987 Jul; 10(1):43-54. PubMed ID: 2885268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal effects of fenoldopam in refractory hypertension.
    Ruilope LM; Robles RG; Miranda B; Tovar J; Alcazar JM; Sancho J; Rodicio JL; Martinez A; Astorga A; Beck T
    J Hypertens; 1988 Aug; 6(8):665-9. PubMed ID: 2903190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Augmentation of renal blood flow and sodium excretion in hypertensive patients during blood pressure reduction by intravenous administration of the dopamine1 agonist fenoldopam.
    Murphy MB; McCoy CE; Weber RR; Frederickson ED; Douglas FL; Goldberg LI
    Circulation; 1987 Dec; 76(6):1312-8. PubMed ID: 2890447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective peripheral dopamine-1 receptor stimulation with fenoldopam in human essential hypertension.
    Carey RM; Stote RM; Dubb JW; Townsend LH; Rose CE; Kaiser DL
    J Clin Invest; 1984 Dec; 74(6):2198-207. PubMed ID: 6150942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of dopamine and fenoldopam effects on renal blood flow and prostacyclin excretion in normal and essential hypertensive subjects.
    Bughi S; Horton R; Antonipillai I; Manoogian C; Ehrlich L; Nadler J
    J Clin Endocrinol Metab; 1989 Dec; 69(6):1116-21. PubMed ID: 2573613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diuresis and natriuresis during continuous dopamine-1 receptor stimulation.
    Hughes JM; Ragsdale NV; Felder RA; Chevalier RL; King B; Carey RM
    Hypertension; 1988 Feb; 11(2 Pt 2):I69-74. PubMed ID: 2894359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective dopamine-1 agonist therapy in severe hypertension: effects of intravenous fenoldopam.
    White WB; Radford MJ; Gonzalez FM; Weed SG; McCabe EJ; Katz AM
    J Am Coll Cardiol; 1988 May; 11(5):1118-23. PubMed ID: 2895780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of fenoldopam on the aldosterone response to metoclopramide in man.
    Dupont AG; Vanderniepen P; Volckaert A; Smitz J; Vansteirteghem AC; Six RO
    Clin Endocrinol (Oxf); 1986 Feb; 24(2):203-8. PubMed ID: 2871951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ontogeny of renal response to specific dopamine DA1-receptor stimulation in sheep.
    Segar JL; Smith FG; Guillery EN; Jose PA; Robillard JE
    Am J Physiol; 1992 Oct; 263(4 Pt 2):R868-73. PubMed ID: 1357989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immediate hemodynamic effects of a dopamine-receptor agonist (fenoldopam) in patients with essential hypertension.
    Ventura HO; Messerli FH; Frohlich ED; Kobrin I; Oigman W; Dunn FG; Carey RM
    Circulation; 1984 Jun; 69(6):1142-5. PubMed ID: 6143625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal and endocrine effects of fenoldopam and metoclopramide in normal man.
    Girbes AR; Smit AJ; Meijer S; Reitsma WD
    Nephron; 1990; 56(2):179-85. PubMed ID: 1978736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of fenoldopam, a dopaminergic agonist, on renal hemodynamics.
    Allison NL; Dubb JW; Ziemniak JA; Alexander F; Stote RM
    Clin Pharmacol Ther; 1987 Mar; 41(3):282-8. PubMed ID: 2880688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective dopamine DA1 stimulation with fenoldopam in cirrhotic patients with ascites: a systemic, splanchnic and renal hemodynamic study.
    Hadengue A; Moreau R; Bacq Y; Gaudin C; Braillon A; Lebrec D
    Hepatology; 1991 Jan; 13(1):111-6. PubMed ID: 1671029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of effect of lithium on the renal response to DA1-dopamine receptor stimulation by fenoldopam in normal man.
    Girbes AR; Smit AJ; Meijer S; Reitsma WD
    Br J Clin Pharmacol; 1990 Apr; 29(4):413-5. PubMed ID: 1970264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective renal dopamine-1 receptor stimulation in man.
    Carey RM; Hughes JM
    Clin Exp Hypertens A; 1987; 9(5-6):1009-20. PubMed ID: 2887311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative DA1-dopamine-receptor agonist and alpha-adrenoceptor antagonist activity of fenoldopam in the anesthetized dog.
    Kohli JD; Glock D; Goldberg LI
    J Cardiovasc Pharmacol; 1988 Jan; 11(1):123-6. PubMed ID: 2450250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.